Aprepitant plus palonosetron and dexamethasone showed early promise for preventing chemotherapy-induced nausea and vomiting among patients with colorectal cancer who are undergoing FOLFOX chemotherapy, according to results of a small pilot study.
Among patients with newly diagnosed, chronic-phase chronic myeloid leukemia, a lower-dose regimen of radotinib demonstrated superior complete cytogenetic response and major molecular response rates at 12 months compared to imatinib.
Chromosome 11p15 abnormalities should be suspected among children with adrenocortical tumors even in the absence of phenotypic signs of genetic growth disorders like Beckwith-Wiedemann syndrome (BWS), according to a retrospective study.
Do you know the 5-year overall survival rate for women with ovarian cancer? How about the response rate for platinum-based chemotherapy in newly diagnosed patients? Test your knowledge on these topics and more in our latest quiz.